Immuno-Oncology & Biomarker Summit 2026

Best Immuno-Oncology Conference In UK In 2026

Immuno-Oncology & Biomarker Summit 2026

πŸ“ Millennium Hotel and Conference Centre Gloucester London
πŸ“… 16–17 March 2026

Days
Hours
Minutes
Seconds

Event Overview

This two-day eventΒ is dedicated to advancing innovation in cancer immunotherapy and biomarker science. The agenda will cover the latest inΒ antibody-drug conjugates (ADCs), bispecific antibodies, cellular therapies, immune checkpoint inhibitors, and novel combination strategies, along with insights into pre-clinical research, translational approaches, and the evolution of personalized immunotherapy.

A strong emphasis will be placed onΒ biomarker discovery, immune monitoring, vaccine development, and the integration of multi-omic platforms. Through cutting-edge sessions and expert-led discussions, the summit will highlight how scientific breakthroughs are reshaping oncology and driving the development of more precise, effective cancer treatments.

The Biomarker Blueprint for Immuno Oncology

Attendees
0 +
Senior Decision Makers
0 +
Speakers
0 +
Sponsors
0 +

Explore The Key Highlights

Next-Generation Immunotherapies

ADCs, bispecific antibodies, and cellular therapies

Biomarker-Driven Precision Oncology

From discovery to clinical impact

Strategic Combination Approaches

Enhancing efficacy and overcoming resistance

Translational Research & Immune Monitoring

Preclinical models and real-time technologies for better decision-making

Biomarker Integration in IO Trials

Advancing cancer vaccines and oncolytic viruses

Who Should Attend

Pharma, Biotech & Industry Professionals in

Immuno-Oncology

Biomarkers

Cell Therapies

Antibodies

Translational Research

Diagnostics

Precision Medicine

Clinical Trials

Drug Development

Commercialization

Cancer Vaccines

Oncolytic Viruses

Genomics

Bioinformatics

Investment

Final Decision Makers

Chief Executive Officer

Chief Scientific Officer

President

Vice President

Executive Director

Assoicate/Senior Director

Manager/Sr. Manager

Head of Department

Attendee Demographics

Why Attend

Exclusive Insights

Latest advances in immuno-oncology, biomarkers, and precision oncology.

Collaboration

Connect with pharma, biotech, and academic leaders.

Combination Strategies

Explore checkpoint inhibitors, ADCs, and cell therapies.

Biomarker Integration

Personalization, trial optimization, and patient selection.

Regulatory Trends

Updates on global frameworks for IO and biomarker-based therapies.

2026 UK Edition Speakers

From Immuno-Oncology Visionaries
to Biomarker Science Pioneers

Join an exceptional lineup of leading experts, and industry innovators advancing the future of cancer care. The 2026 edition will bring together influential voices from pharmaceutical and biotech companies, academic research centers, regulatory bodies, and diagnostic developersβ€”covering the full spectrum of immunotherapy, biomarker discovery, translational research, and precision oncology.

Vassela Vassileva

Andrew Pierce

Senior Vice President - Discovery & Development, Owkin, UK

Andrew Pierce

Andrew Pierce

Senior Vice President - Discovery & Development, Owkin, UK

Angelica Loskog

Angelica Loskog

CEO, Lokon Pharma AB, Sweden

Barbara Cipriani

Barbara Cipriani

Vice President, R&D, Pathios Therapeutics, UK

Colin Self

Colin Self

Managing Director, Precision Immunotherapeutics Ltd, UK

Douglas Palmer

Douglas Palmer

Executive Director Head IO Translational Medicine, AstraZeneca, USA

Eleonora Peerani

Eleonora Peerani

Director, Precision Medicine R&D, Pear Bio, UK

John Bridgeman

John Bridgeman

Chief Scientific Officer and Co-founder, ImmunoKey, UK

John Maher

John Maher

Chief Scientific Officer, Leucid Bio, UK

Louis Boon

Louis Boon

CSO, JJP Biologics, Netherlands

Mark Eccleston

Mark Eccleston

CEO, ValiRx, UK

Nick Tribble

Nick Tribble

Associate Director Antibody Discovery & Protein Science, Cancer Research UK

Simon Plyte

Simon Plyte

Chief Scientific Officer, BIOMUNEX Pharmaceuticals, France

Prasun Chakraborty

Prasun Chakraborty

Founder, CEO, Genevation Ltd. UK

Seema Patel

Seema Patel

Immuno-oncology Alliance Science Program Lead, LifeArc, UK

Manel Kraiem

Manel Kraiem

Chief Development Officer, Skymab Biotherapeutics, France

Robert Boyd

Robert Boyd

Chief Scientific Officer, Elasmogen Ltd, UK

Sophia Karagiannis

Sophia Karagiannis

Professor, Translational Cancer Immunology, King’s College London, UK

Tiffany Thorn

Tiffany Thorn

Founder, CEO, BiVictriX Therapeutics, UK

Chandan Seth Nanda

Chandan Seth Nanda

CEO, Founder, Deep Biotech Company UK

Denarda Dangaj

Denarda Dangaj

Group Leader, Tumor Microenvironment and Biomarker Discovery, CHUV, Switzerland

Jon Moore

Jon Moore

CSO, Epitopea, UK

Kathrin Heinzmann

Robert Boyd

Biomarker Development Specialist, Cancer Research UK

Amit Jathoul

Amit Jathoul

Founder, CEO, Bioflares Ltd. UK

Agenda

Our Esteemed Sponsors & Exhibitors

Bronze Sponsor

Exhibitors

Media Partners

LISTING PARTNERS​

Past Edition Sponsors

Why Sponsor?

Dedicated Prime Speaking Slot

Exhibition Opportunity

One-to-One Meetings

Pre-Qualified Leads

High-Level Networking

Brand Impact

View The Glimpses Of Our Past Edition

View The Glimpses Of Our Past Edition

TheΒ inaugural EVIDENCE 360 SummitΒ took place onΒ 26–27 May 2025 in Frankfurt, Germany, bringing together leaders from across the pharmaceutical, biotech, payer, and regulatory communities.
Β 
Over two dynamic days, the summit hostedΒ insightful discussions, case studies, and panel debatesΒ on the evolving role of real-world evidence in shaping pricing, reimbursement, and market access strategies.
Β 
The Frankfurt edition established the EVIDENCE 360 Summit as aΒ leading platform for advancing RWE strategies, offering unparalleled opportunities to exchange ideas, build collaborations, and explore solutions that will define the future of healthcare access.

Evidence 360 USA Edition

Elevate your brand where crypto’s most influential minds connect beyond the conference floor.

Venue

Millennium Hotel and Conference Centre Gloucester London

Venue Gallery

Contact Our Team Today

Where collaborations spark and the future of Immuno-Oncology and
Biomarker innovation begins.
For Speaking &
Partnerships
Nikita Patankar Parab
Founder, Managing Director
For Sponsorship & Delegation
Prativa Sinha
Director
loader

Download Agenda